TFP Bureau, Raipur, November 11, 2025. The Chhattisgarh Medical Services Corporation Limited (CGMSC) has blacklisted three medicines for a period of three years after they failed government and NABL-accredited laboratory quality tests. The action, taken under the Corporation’s “Zero Tolerance Policy,” prohibits the concerned suppliers from participating in any new tenders during the blacklist period.
According to CGMSC, two products supplied by M/s AG Parenterals, Baddi (Himachal Pradesh)—Calcium (Elemental) with Vitamin D3 Tablets and Ornidazole Tablets—were declared “Not of Standard Quality (NSQ)” following laboratory analysis. Heparin Sodium 1000 IU/ml Injection IP, supplied by M/s Divine Laboratories Pvt. Ltd., Vadodara, was similarly found substandard in tests conducted at NABL-accredited labs and the Central Drugs Laboratory (CDL), Kolkata.
All three products have been immediately blacklisted as per tender conditions.
CGMSC stated that stringent quality assurance measures—batch-wise testing, re-testing, and immediate corrective action—are integral to its operations. The Corporation said all steps are taken strictly in accordance with the CDSCO framework and the Drugs and Cosmetics Act, 1940, and Rules, 1945, to ensure only quality-assured medicines reach patients in the state.
Health Minister Shyam Bihari Jaiswal said patient safety remains the top priority and emphasised that no compromise on drug quality will be tolerated. He asserted that strict action will continue against any supplier found violating quality standards.
